recurrent kidney stone disease

source: pixabay.com

Phase 2 Study For Recurrent Kidney Stone Disease is on Track to Begin Soon

Post author:Trudy Horsting
Post published:February 22, 2022
Post category:Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals has just announced that they will be starting a Phase 2 trial for their RNAi therapeutic called Lumasiran. This trial will investigate both the safety as well as…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More